Letter

Importance of health economics must be recognised when trials are designed

BMJ 1999; 318 doi: 10.1136/bmj.318.7199.1696a (Published 19 June 1999)
Cite this as: BMJ 1999;318:1696.2

Access to the full text of this article requires a subscription or payment. Please log in or subscribe below.

  1. Alan Haycox, Senior lecturer in health economics (A.R.Haycox@liverpool.ac.uk),
  2. Adrian Bagust, Senior research fellow,
  3. Tom Walley, Director
  1. Prescribing Research Group, Department of Pharmacology and Therapeutics, University of Liverpool

    EDITOR—Barbert and Thompson's study is welcome if it leads trial designers to recognise health economics as more than a (non-essential) afterthought to their trial.1 The points that the authors make would benefit from a more complete understanding of the nature of economic data and the context in which economic analyses are undertaken.2

    Clinical outcomes in trials tend to be uni-dimensional and unambiguous (such as survival or response to treatment), whereas economic data are essentially multidimensional. Health care embraces the use of …

    Access to the full text of this article requires a subscription or payment

    Subscribe

    Article access

    Article access for 1 day

    Purchase this article for £20 $30 €32*

    The PDF version can be downloaded as your personal record

    * Prices do not include VAT

    Rapid responses

    THIS WEEK'S POLL

    Read related article

    See previous polls

    BMJ most popular